SAN DIEGO, Aug. 26, 2014 /PRNewswire/ -- Profil Institute for Clinical Research, Inc., an early phase clinical research organization (CRO) focused on diabetes and obesity, announced today a milestone in clinical research for diabetes with the completion of more than 200 phase I – IIa clinical trials encompassing every clinically relevant drug class for the treatment of type 1 and type 2 diabetes.
"The significance of this vast amount of research is what it represents for the public domain," said Dan Bradbury, former Amylin Pharmaceutical CEO, managing member of BioBrit, LLC, and member of Profil Institute's Board of Directors. "Science driven results, as well as advances in clinical research methodologies by Profil Institute have contributed substantially to our understanding of new treatment opportunities and of how early phase clinical research in diabetes and obesity can be conducted in the most meaningful and efficient way. As a result, we've seen significant progress toward better treatments for both type 1 and type 2 diabetes."
"The sense of urgency related to the diabetes epidemic is increasing with the rapid global rise of diabetes," said Dr. Marcus Hompesch, Profil Institute CEO. "We've contributed important research to many current therapies providing exciting new treatment options for patients, but we have to continue to outpace ourselves to make an impact on diabetes worldwide. We a have long, yet promising, path of opportunities in metabolic research as we turn our attention to biomarker discovery to predict and support the treatment of cardiometabolic diseases, as well as looking at novel combination therapies using existing drugs.
"More than a decade ago we decided to focus on diabetes, obesity and cardiometabolic clinical research because, as a group of scientists, that was at the center of our research and was where we hoped to make the most significant impact on science and patient care. Today we're pleased that through our commitment to science, clinical research and drug development, we have built the teams, infrastructure, technology and expertise that have allowed us to accumulate the knowledge and experience to benefit diabetes research as a whole."
Profil Institute is the only CRO in the U.S. therapeutically and scientifically focused exclusively on early phase diabetes and obesity clinical research and development. Profil Institute has invested in its scientific expertise, including doctorate level scientists that make up more than 20% of Profil Institute's workforce, and in advancing its Automated Glucose Clamp technology and other key research methods. The company's experience in early phase clinical studies includes every clinical relevant drug class, as well as nearly all modes of administration and blood glucose monitoring devices. Of the 200 early phase clinical studies completed, 45% of those studies involved study participants with type 2 diabetes, 20% with type 1 diabetes, 20% with healthy study participants, and 15% involved specialized populations, including participants with cardiovascular disease, kidney disease or insulin resistance.
About Profil Institute for Clinical Research, Inc.
Profil Institute for Clinical Research, Inc. is a science driven, early phase clinical research organization (CRO) focused on diabetes and obesity. It is renowned for its scientific expertise, depth of services, expanded scope of research methodologies, and experience with every clinically relevant drug class in diabetes. The company provides end-to-end early phase services from consulting for strategic clinical development and regulatory planning through design and completion of complex clinical trials, including the reporting and publication of final study results.
Profil Institute's expertise and experience encompasses small and large molecule therapies, biologics and biosimilars through all routes of administration, as well as devices. The company's clients range from large pharma and drug discovery companies to small virtual companies throughout the Americas, Europe and Asia.
Profil Institute is also recognized internationally as an innovator of methodologies to improve the quality of metabolic research, including its Automated Glucose Clamp technology. As the leading early phase CRO focused on diabetes and obesity, Profil Institute is driving new, higher standards in metabolic clinical research through collaborative science with key academic and industry partners and its Metabolic Research Partners™ program.
For more information, please visit www.profilinstitute.com.
|SOURCE Profil Institute for Clinical Research, Inc.|
Copyright©2014 PR Newswire.
All rights reserved